spacer
home > ict > summer 2008 > recruiting and retaining
PUBLICATIONS
International Clinical Trials

Recruiting and Retaining

THE IMPORTANCE OF EXPERT PLANNING

Hitting study timelines means that a successful recruitment process is in place. Making this happen requires expert planning. At study start-up, when timeline pressure is at its greatest – due to investigator meetings or ambitious goals set by senior management – clinical teams often forego the very planning they need in order to prevent recruitment delays. On the surface, many think recruitment planning could take weeks to complete, but depending on the study it can be turned around in days.

Recruitment planning requires a combination of statistical modelling of different recruitment scenarios. It also requires analysis of the study from the patients’ perspective, often achieved through focus groups or interviews. It is important to understand where and when any stumbling blocks are likely to occur. For example, it is important to determine the point at which clinical trial fatigue (CTF) may set in, or what aspect of the study may be the patients’ breaking point, by asking: ‘What would you do if you were asked to do this procedure?’ It sounds simple, but finding the right population within the right timeframe means doing your homework. This includes looking at feasibility data, setting schedules, evaluating metrics, and reviewing budget parameters.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Liz Moench has served as CEO and President of MediciGlobalTM since 1992. She has helped to improve the patient recruitment and retention process for clinical trials, as well as leading the life sciences industry in creativity and systems for patient recruitment and retention. Prior to founding MediciGlobal, Liz served as Corporate Vice President of Communications and Public Affairs and was a member of the worldwide corporate management committee of Rhone-Poulenc Rorer (now Sanofi-Aventis), leading them in their first proactive patient recruitment programme for the cancer drug Taxotere. Liz has received numerous marketing-communications awards, and has also been active in leading industry associations.
spacer
Liz Moench
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement